MGI Tech Signs Exclusive Licensing Agreement with Swiss Rockets AG for CoolMPS™ Sequencing Technology

A major development has emerged in the global biotechnology industry, as MGI Tech Co., Ltd. and Swiss Rockets AG have announced an exclusive licensing agreement aimed at expanding access to MGI’s groundbreaking CoolMPS sequencing technology. This deal of MGI Tech and Swiss Rockets licensing agreement marks a significant milestone in MGI’s strategy to globalize its innovative sequencing solutions, strengthening its presence beyond Asia and accelerating advancements in genomics research worldwide. The partnership also positions Swiss Rockets AG as a key player in bringing next-generation sequencing technology to new markets. But there’s more to know about this strategic alliance — keep reading to learn how this patent licensing could reshape the future of genomic science and precision medicine.

What is the Purpose of the MGI Tech and Swiss Rockets licensing agreement?

Before understanding the impact of this MGI Tech and Swiss Rockets licensing agreement collaboration, it’s important to look at the key details of the agreement. The deal was officially announced on October 28, 2025, between MGI Tech Co., Ltd. and Swiss Rockets AG, marking the signing of an exclusive licensing agreement for MGI’s proprietary CoolMPS sequencing technology. Signed through MGI’s U.S. subsidiaries, MGI US LLC and Complete Genomics Inc., the agreement gives Swiss Rockets AG exclusive rights to use CoolMPS-based sequencing products across all global markets outside the Asia-Pacific and Greater China regions. The partnership is considered “exclusive” because Swiss Rockets AG will be the sole company authorized to use and distribute this technology in those territories.

In addition, the agreement covers MGI’s intellectual property rights (IPR), including patents, proprietary know-how, and related software, as well as non-exclusive access to specific accessory and consumable products. This collaboration sets the foundation for both companies to expand the global reach of next-generation sequencing solutions and drive innovation in genomics and precision medicine.

The CoolMPS technology is known for its antibody-based fluorescent recognition chemistry, which enables high-precision sequencing with read lengths of up to 600–700 bases on MGI’s DNBSEQ platform. This advanced method allows for more accurate, efficient, and cost-effective analysis

Read Also: Nokia Signs Patent Licensing Deal with Starz to Expand Streaming Technology Portfolio

What Is the Global Impact of the MGI Tech For the CoolMPS Licensing Agreement Deal?

To understand the importance of this agreement, it’s essential to first look at its potential impact on the global genomics and biotechnology landscape. The exclusive licensing deal between MGI Tech and Swiss Rockets AG is expected to bring far-reaching changes to the industry by accelerating innovation and expanding access to advanced sequencing technologies worldwide, such as:

• For MGI Tech, the agreement marks a strategic step toward globalizing its proprietary CoolMPS sequencing technology, allowing the company to extend its market reach and monetize its intellectual property beyond Asia without establishing direct operations. 
• Meanwhile, for Swiss Rockets AG, the partnership provides access to a cutting-edge sequencing platform that will strengthen its presence in precision medicine, oncology, viral disease research, and longevity sciences, enabling the company to deliver more sophisticated genomic solutions on a global scale.
• From a broader industry perspective, this collaboration is likely to boost competition and innovation in the next-generation sequencing (NGS) market by offering longer, more accurate, and cost-efficient reads — a move that could challenge existing players. 

Conclusion

The exclusive licensing agreement between MGI Tech and Swiss Rockets AG marks a significant milestone in the global expansion of next-generation sequencing technology. This deal not only reflects the growing importance of strategic licensing in biotechnology but also highlights how global cooperation can drive the future of genomic research and personalized healthcare.

Read Also: Difference Between Patent Licensing vs Franchising, and Which One Is Right for Your Business?